Orenetide for the treatment of hypoactive sexual desire disorder: results of a randomized placebo-controlled trial
- Autores: Sukhikh G.T.1, Smulevich A.B.2, Stenyaeva N.N.1, Nemenov D.G.3, Prilepskaya V.N.1, Khritinin D.F.4, Myasoedov N.F.5, Matskevich A.A.3, Andreeva L.A.5, Zelenina E.V.1
-
Afiliações:
- Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation
- Psychiatric Hospital No. 1 named after N.A. Alexeev, Department of Health of Moscow
- IVIX Ltd
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
- Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»
- Edição: Nº 8 (2022)
- Páginas: 95-106
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/249549
- DOI: https://doi.org/10.18565/aig.2022.8.95-106
- ID: 249549
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
Gennadiy Sukhikh
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian FederationAcademician of the RAS, Dr. Med. Sci., Professor, Director
Anatoliy Smulevich
Psychiatric Hospital No. 1 named after N.A. Alexeev, Department of Health of MoscowAcademician of the RAS, Dr. Med. Sci., Professor, Head of the Department for the Study of Borderline Mental Pathology and Psychosomatic Disorders, MHRC
Natalia Stenyaeva
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian FederationPhD, Senior Researcher
Daniil Nemenov
IVIX LtdM.D., Chief executive officer
Vera Prilepskaya
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian FederationDr. Med. Sci., Professor, Head of the Scientific Polyclinic Department
Dmitriy Khritinin
I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)Corresponding Member of the RAS, Dr. Med. Sci., Professor at the Department of Psychiatry and Narcology of the NV. Sklifosovsky Institute of Clinical Medicine
Nikolay Myasoedov
Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»Academician of the RAS, Dr. Chem. Sci., Professor, Head of the Laboratory of Molecular Pharmacology of Peptides
Aleksey Matskevich
IVIX LtdPhD (Bio), Chief Researcher
Lyudmila Andreeva
Institute of Molecular Genetics of National Research Centre «Kurchatov Institute»Deputy Head of the Laboratory of Molecular Pharmacology of Peptides, Head of the Regulatory Peptides Sector of the Physiologically Active Substances Chemistry Department
Elena Zelenina
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian FederationPhD, psychiatrist
Bibliografia
- McCabe M.P., Sharlip I.D., Atalla E., Baton R., Fisher A.D., Laumann E. et al. Definitions of sexual dysfunctions in women and men: A consensus statement from the fourth international consultation on sexual medicine 2015. J. Sex. Med. 2016; 13(2): 135-43. https://dx.doi.org/10.1016/j.jsxm.2015.12.019.
- Rosen R.C., Connor M.K., Miyasato G., Link C., Shifren J.L., Fisher W.A. et al. Sexual desire problems in women seeking healthcare: a novel study design for ascertaining prevalence of hypoactive sexual desire disorder in clinic-based samples of U.S. women. J. Womens Health (Larchmt). 2012; 21(5): 505-15. https://dx.doi.org/10.1089/jwh.2011.3002.
- Simon J.A. Low sexual desire - is it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder. Postgrad. Med. 2010; 122(6): 128-36. https://dx.doi.org/10.3810/pgm.2010.11.2230.
- Clayton A.H., Kingsberg S.A., Goldstein I. Evaluation and management of hypoactive sexual desire disorder. Sex. Med. 2018; 6(2): 59-74. https://dx.doi.org/10.1016/j.esxm.2018.01.004.
- Kingsberg S.A., Clayton A.H., Pfaus J.G. The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder. CNS Drugs. 2015; 29(11): 915-33. https://dx.doi.org/10.1007/s40263-015-0288-1.
- Sobecki J.N., Curlin F.A., Rasinski K.A., Lindau S.T. What we don’t talk about when we don’t talk about sex: results of a national survey of U.S. obstetrician/gynecologists. J. Sex. Med. 2012; 9(5): 1285-94. https://dx.doi.org/10.1111/j.1743-6109.2012.02702.x.
- Nappi R.E., Gardella B. What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions? Expert Opin. Pharmacother. 2019; 20(7): 777-9. https://dx.doi.org/10.1080/14656566.2019.1582644.
- Joffe H.V., Chang C., Sewell C., Easley O., Nguyen C., Dunn S. et al. FDA approval of flibanserin - treating hypoactive sexual desire disorder. N. Engl. J. Med. 2016; 374(2): 101-4. https://dx.doi.org/10.1056/NEJMp1513686.
- Dhillon S., Keam S.J. Bremelanotide: first approval. Drugs. 2019; 79(14): 599606. https://dx.doi.org/10.1007/s40265-019-01187-w.
- Andreev-Andrievskiy A., Lomonosov M., Popova A., Lagereva E., Clement P., Salimov R. et al. BP101 peptide promotes female sexual receptivity in the rat. J. Sex. Med. 2017; 14(3): 336-46. https://dxdoi.org/10.1016/j.jsxm.2017.01.008.
- Agmo A., Soria P. GABAergic drugs and sexual motivation, receptivity and exploratory behaviors in the female rat. Psychopharmacology (Berlin). 1997; 129(4): 372-81. https://dx.doi.org/10.1007/s002130050203.
- Crickmore M.A., Vosshall L.B. Opposing dopaminergic and GABAergic neurons control the duration and persistence of copulation in drosophila. Cell. 2013; 155(4): :881-93. https://dx.doi.org/10.1016/j.cell.2013.09.055.
- Rodnguez-Manzo G., Canseco-Alba A. A new role for GABAergic transmission in the control of male rat sexual behavior expression. Behav. Brain Res. 2017; 320: 21-9. https://dx.doi.org/10.1016/j.bbr.2016.11.041.
- Seney M., Chang L.-C., Oh H., Wang X., Tseng G.C., Lewis D. et al. The role of genetic sex in affect regulation and expression of GABA-related genes across species. Front. Psychiatry. 2013; 4: 104. https://dx.doi.org/10.3389/fpsyt.2013.00104.
- Maejima S., Abe Y., Yamaguchi S., Musatov S., Ogawa S., Kondo Y. et al. VGF in the medial preoptic nucleus increases sexual activity following sexual arousal induction in male rats. Endocrinology. 2018; 159(12): 3993-4005. https://dx.doi.org/10.1210/en.2018-00804.
- Wei Y.C., Wang S.R., Jiao Z.L., Zhang W., Lin J.K., LiX.Y. et al. Medial preoptic area in mice is capable of mediating sexually dimorphic behaviors regardless of gender. Nat. Commun. 2018; 9(1): 279. https://dx.doi.org/10.1038/s41467-017-02648-0.
- Yamaguchi S., Abe Y., Maejima S., Tsukahara S. Sexual experience reduces neuronal activity in the central part of the medial preoptic nucleus in male rats during sexual behavior. Neurosci. Lett. 2018; 685: 155-9. https://dx.doi.org/10.1016/j.neulet.2018.08.037.
- Lindau S.T., Schumm L.P., Laumann E.O., Levinson W., O’Muircheartaigh C.A., Waite L.J. A Study of sexuality and health among older adults in the United States. N. Engl. J. Med. 2007; 357(8): 762-74. https://dx.doi.org/10.1056/NEJMoa067423.
- Nemenov D., Lomonosov M., Golikov D. 150 BP101 new molecule for HSDD treatment - results of proof-of-concept phase 2a study. J. Sex. Med. 2018;15: S41-2. https://dx/doi.org/10.1016/j.jsxm.2017.11.108.
- Shifren J.L., Monz B.U., Russo P.A., Segreti A., Johannes C.B. Sexual problems and distress in united states women: prevalence and correlates. Obstet. Gynecol. 2008; 112:(5): 970-8. https://dx.doi.org/10.1097/AOG.0b013e3181898cdb.
- Nappi P.R.E., Cucinella L., Martella S., Rossi M., Tiranini L., Martini E. Female sexual dysfunction (FSD): prevalence and impact on quality of life (QoL). Maturitas. 2016; 94: 87-91. https://dx.doi.org/10.1016/j.maturitas.2016.09.013.
- Revicki D.A., Margolis M.K., Bush E.N., DeRogatis L.R., Hanes V. Content validity of the female sexual function index (FSFI) in preand postmenopausal women with hypoactive sexual desire disorder. J. Sex. Med. 2011; 8(8): 2237-45. https://dx.doi.org/10.1111/j.1743-6109.2011.02312.x.
- Althof S.E. Outcome measurement in female sexual dysfunction clinical trials. J. Sex Marital Ther. 2005; 31(3): 153-66. https://dx.doi.org/10.1080/00926230590909989.
- Meston C.M. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J. Sex Marital Ther. 2003; 29(1): 39-46. https://dx.doi.org/10.1080/713847100.
- Derogatis L., Clayton A., Lewis-D’Agostino D., Wunderlich G., Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J. Sex. Med. 2008; 5(2): 357-64. https://dx.doi.org/10.1111/j.1743-6109.2007.00672.x.
- Portman D.J., Brown L., Yuan J., Kissling R., Kingsberg S.A. Flibanserin in postmenopausal women with hypoactive sexual desire disorder: Results of the PLUMERIA Study. J. Sex. Med. 2017; 14(6): 834-42. https://dx.doi.org/10.1016/j.jsxm.2017.03.258.
- Clayton A.H., Althof S.E., Kingsberg S., DeRogatis L.R., Kroll R., Goldstein I. et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (London). 2016; 12(3): 325-37. https://dx.doi.org/10.2217/whe-2016-0018.